Mol Cancer Ther 1 : 545552 Rees C, Beale P, Trigo JM, Mitchell F, Jackman A, Smith R, Douglass E, Judson I (2003) Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies
Each strip has been formulated with Brain Heart Infusion Media that allows for the maximum cultivation of fastidious bacteria, such as streptococci, pneumococci and meningococci, found in water samples
It consists of the tripeptide glycyl-L-histidyl-L-lysine complexed with a divalent copper ion, forming a high-affinity chelate that facilitates controlled copper delivery within biological systems
doi: 10.3389/fphar.2021.718147 Received 09 June 2021 Accepted 17 November 2021 Published 13 December 2021 Volume 12 - 2021 Edited by Fan Jiang, Shandong University, China Reviewed by Dechang Chen, Shanghai Jiao Tong University, China Ying Li, Xian Jiaotong University, China Updates Copyright 2021 Tepes, Gojkovic, Krezic, Zizek, Vranes, Madzar, Santak, Batelja, Milavic, Sikiric, Kocman, Simonji, Samara, Knezevic, Barisic, Lovric, Strbe, Kokot, Sjekavica, Kolak, Skrtic, Seiwerth, Boban Blagaic and Sikiric
Results The AngIV Analog D-Nle-Tyr-Ile-NH(CH 2 ) 5 CONH 2 is More Metabolically Stable than Norleual (Nle-Tyr-Leu--(CH 2 NH 2 ) 3-4 -His-Pro-Phe (SEQ ID NO: 1): The AngIV-related peptidomimetic Norleual was previously shown to possess, anti-HGF/Met, anti-angiogenic, and anti-cancer activities (Yamamoto et al., 2010)
